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Abstract
Sphingolipids play a role in the development of emphysema and ceramide levels are increased in experimental models of
emphysema; however, the mechanisms of ceramide-related pulmonary emphysema are not fully understood. Here we
examine mechanisms of ceramide-induced pulmonary emphysema. Male Sprague-Dawley rats were treated with fenretinide
(20 mg/kg BW), a synthetic derivative of retinoic acid that causes the formation of ceramide, and we postulated that the
effects of fenretinide could be offset by administering sphingosine 1-phosphate (S1P) (100 mg/kg BW). Lung tissues were
analyzed and mean alveolar airspace area, total length of the alveolar perimeter and the number of caspase-3 positive cells
were measured. Hypoxia-inducible factor alpha (HIF-1a), vascular endothelial growth factor (VEGF) and other related
proteins were analyzed by Western blot analysis. Immunohistochemical analysis of HIF-1a was also performed. Ceramide,
dihydroceramide, S1P, and dihydro-S1P were measured by mass spectrometer. Chronic intraperitoneal injection of
fenretinide increased the alveolar airspace surface area and increased the number of caspase-3 positive cells in rat lungs.
Fenretinide also suppressed HIF-1a and VEGF protein expression in rat lungs. Concomitant injection of S1P prevented the
decrease in the expression of HIF-1a, VEGF, histone deacetylase 2 (HDAC2), and nuclear factor (erythroid-derived 2)-like 2
(Nrf2) protein expression in the lungs. S1P injection also increased phosphorylated sphingosine kinase 1. Dihydroceramide
was significantly increased by fenretinide injection and S1P treatment prevented the increase in dihydroceramide levels in
rat lungs. These data support the concept that increased de novo ceramide production causes alveolar septal cell apoptosis
and causes emphysema via suppressing HIF-1a. Concomitant treatment with S1P normalizes the ceramide-S1P balance in
the rat lungs and increases HIF-1a protein expression via activation of sphingosine kinase 1; as a consequence, S1P salvages
fenretinide induced emphysema in rat lungs.
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Introduction
Chronic obstructive pulmonary disease (COPD), and particu-
larly emphysema, is a major and increasingly recognized global
health problem and chronic lung tissue destruction determines a
large component of the pathogenesis and morbidity of patients
with this disease [1,2]. Although chronic inflammation has been
identified as an important finding and documented histologically
[3–5], the cellular and molecular details of lung tissue destruction
are still incompletely understood [6,7].
Vascular endothelial growth factor (VEGF) has been proposed
to be an integral part of the homeostatic adult lung structure
maintenance program [8] and the expression of the VEGF ligand
and the VEGF receptor 2 (VEGFR2 (KDR)) proteins has been
shown to be decreased in human lung tissue and airway samples
from patients with severe COPD/emphysema [9,10]. The finding
that the VEGF receptor blocker SU5416 induces pulmonary
emphysema has been reported from our laboratory [11] and
Petrache et al showed that SU5416 caused emphysema in mice
[12] is associated with pulmonary ceramide generation [12]. Thus,
mechanistically this SU5416-induced emphysema model can be
explained by VEGF receptor blockade- related lung cell apoptosis
and oxidative stress [13] driven by intracellular ceramide [12].
Consistent with this concept, Diab et al. also reported that
stimulation of sphingosine 1-phosphate (S1P) signaling prevented
the SU5416 VEGF receptor blockade-induced emphysema in
mice [14], hypothesizing that a homeostatic balance between
ceramide and S1P was disturbed by VEGF receptor blockade, and
that S1P can restore this disturbed balance [14].
S1P is a highly bioactive sphingolipid metabolite involved in
many cellular processes including proliferation, survival, and
migration, as well as tissue responses such as angiogenesis and
responses to allergens [15]. Whereas the role of S1P in the
pathogenesis of asthma has been investigated [16], its contribution
to the pathogenesis of COPD/emphysema is poorly understood
[17].
S1P can activate HIF-1a in vascular cells [18]. We had recently
demonstrated reduced HIF-1a protein expression in lungs from
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COPD patients [19]. Therefore, we hypothesized that S1P may
induce HIF-1a in the lung tissue and may induce HIF-1a target
genes and proteins, and thus may protect the lung against
emphysema development. Here, we use fenretinide, an intracel-
lular ceramide inducer, to generate emphysematous changes in the
rat lung and examine whether fenretinide would cause emphyse-
ma by increasing ceramide production. We examined whether
fenretinide-induced airspace enlargement was associated with a
Figure 1. Morphological analysis of the lungs from fenretinide challenged rats treated with or without sphingosine 1-phosphate
(S1P). When compared to control lungs (A), the low power magnification shows air-space enlargement in the chronic fenretinide treated rat lungs
(B). Examples of data based on concurrent S1P administration and S1P alone treatment are shown in (C) and (D), respectively. Quantitative analysis is
shown in (E). Data are expressed as mean 6 SEM. C=Control, F = Fenretinide, S = S1P Bars = 250 mm, Original Magnification x40.
doi:10.1371/journal.pone.0053927.g001
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reduction of lung tissue HIF-1a and investigated whether S1P
could restore the tissue expression of HIF-1a and prevent
fenretinide-induced airspace enlargement.
Materials and Methods
Chemicals
Chemicals and materials were obtained from the following
sources: S1P was from Cayman chemical (Ann Arbor, MI),
Fenretinide was from Tocris bioscience (Ellisville, MO), the ECL
system (Western LighteningH and Western LighteningH plus-ECL)
was from PerkinElmer (Waltham, MA); NE-PERH Nuclear and
Cytoplasmic Extraction Reagents were from Thermo Scientific
(Rockford, IL); 4–12% Bis-Tris Nupage gels, and MES-SDS
running buffer were from Invitrogen (Carlsbad, CA); the
polyvinylidene difluoride (PVDF) membranes was from Bio-Rad
Laboratories (Richmond, CA); the protease inhibitor cocktail was
from Roche Applied Science (Indianapolis, IN); positive control of
HIF-1a protein, rabbit anti-VEGF polyclonal antibody, mouse
anti-Akt monoclonal antibody, rabbit anti-phospho Akt (pAkt)
polyclonal antibody, rabbit anti-Nrf2 polyclonal antibody, mouse
anti-HIF-1a monoclonal antibody, rabbit anti-HDAC2 polyclonal
antibody, goat anti-Lamin B polyclonal antibody, and horseradish
peroxidase-conjugated goat anti-mouse and rabbit, and donkey
anti-goat IgG were from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Rabbit anti-active Caspase-3 antibody was from Cell
Signaling Technology Inc. (Danvers, MA). Rabbit anti-phospho
specific sphingosine kinase 1 antibody and rabbit anti-sphingosine
Figure 2. Mass spectrometric analysis of dihydroceramide and long chain ceramide species. The concentrations of dihydroceramide in
the rat lungs are shown (A). The individual data of the dihydroceramide species are depicted graphically and numerically (B). Data are expressed as
mean 6 SEM. C=Control, F = Fenretinide, S = S1P.
doi:10.1371/journal.pone.0053927.g002
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kinase 1 polyclonal antibody were from ECM biosciences
(Versailles, KY). VectastainH Elite ABC-Peroxidase Kits Universal
was from Vector Laboratories (Burlingame, CA). Liquid diami-
nobenzidine (DAB) substrate chromogen system was from Dako
North America Inc. (Carpinteria, CA). All other chemicals were
purchased from Sigma (St. Louis, MO).
Animal Experimental Protocols. The study was carried out
in strict accordance with the recommendations published in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of the Health Guidelines for the Care and Use of
Laboratory Animals (IACUC) and approved by the Virginia
Commonwealth University’s Institutional Animal Care and Use
Committee (Protocol Number: AM10162 Pathobiology of Em-
physema). Fenretinide was dissolved in 1:1:6 of ethanol,
CremophorH (Sigma) and normal saline. S1P was dissolved in
3% fatty acid free bovine serum albumin in phosphate buffered
saline (PBS). Adult male Sprague-Dawley rats (200 g) were
injected intraperitoneally with 20 mg/kg body weight of fenreti-
nide two times per week for 4 weeks. S1P was injected
intraperitoneally (100 mg/kg body weight) five days per week for
4 weeks, starting on day 1 of the fenretinide injections. The dosing
and treatment schedule of fenretinide and S1P injection was based
on previously published reports [20,21]. Control rats received only
solvents ((1:1:6 of ethanol, CremophorH, normal saline) and 3%
fatty acid free bovine serum albumin (Sigma)) in PBS. For the
entire study we used the following numbers of rats: control (n = 6),
fenretinide (n = 5), S1P (n = 5), and fenretinide and S1P (n = 4). All
surgery was performed under sodium pentobarbital anesthesia,
and every effort was made to minimize pain and distress.
Morphometry. Lungs were inflated with 0.5% low-melting
agarose at a constant pressure of 25 cm H2O, fixed in 10%
formalin for 48 hours and paraffin-embedded by standard
techniques. Sections (5 mm) were stained with hematoxylin and
eosin. Images were acquired with a Carl Zeiss AxioCam color
camera (Carl Zeiss Vision GmbH, Hallbergmoos, Germany) and
analyzed using AxioVisionH Imaging System software (Carl Zeiss
Vision GmbH). 10 random lung fields per tissue section were
captured at a 1006magnification, and then AxioVisionH Imaging
System software was used to measure the mean alveolar airspace
areas (MAA) and total length of alveolar perimeters (TLAP) in
pixels per mm2.
Western blot analysis. Cytoplasmic and nuclear proteins
from lungs were prepared using NE-PER Nuclear and
Cytoplasmic Extraction Reagents based on the manufacturer’s
protocol (Pierce, Rockford, IL), and the protein extracts were
analyzed for protein content using a Bradford protein assay [22].
Each sample was quantified, and then 40 mg of protein
(cytoplasmic protein) or 20 mg of protein (nuclear protein) was
loaded into each lane of a 4–12% Bis-Tris Nupage gel with MES
SDS running buffer, according to the manufacturer’s protocol.
The gel was transferred to a PVDF membrane by electrophoresis
at 100 V for 1 to 1.5 hour. The membrane was blocked in PBS,
0.2% Tween 20 (PBS-T), and 5% nonfat milk at room
temperature for 1 hour. All antibodies were diluted in the same
blocking buffer. The membrane was then probed with the
primary antibodies. Subsequently, membranes were incubated
with horseradish peroxidase-conjugated goat anti-mouse, goat
anti-rabbit, or donkey anti-goat antibody. The ECL system was
used for detection of the proteins.
Immunohistochemical staining for active Caspase-3 and
HIF-1a. The slides with 5 mm paraffin sections were deparaffi-
nized in xylene, rehydrated by serial immersions in 100% ethanol,
95% ethanol, 70% ethanol, and then washed with PBS. Then the
sections were rehydrated and submitted to microwave treatment
(800 W/15 min) in 10 mM citric acid monohydrate solution, and
then quenching of endogenous peroxidase with 3% H2O2 for 15
minutes. Sections were incubated overnight with anti-cleaved
caspase-3 rabbit polyclonal antibody (1:200 dilution) or anti- HIF-
1a-mouse monoclonal antibody (1:10 dilution) at 4uC and then
were incubated with rabbit (for active caspase-3) or mouse (for
HIF-1a)-labeled polymer horseradish (HRP) peroxidase for
30 min at room temperature. Following the secondary antibody
application, sections were incubated with ABC complex (Vector,
Burlingame, CA) for 30 min at room temperature, rinsed in PBS,
and developed with diaminobenzidine (DAB; Vector, Burlingame,
CA) and hydrogen peroxide. Washing with water stopped the
DAB reaction. A light hematoxylin counterstain was applied.
Sections were dehydrated by sequential immersion in 70%
ethanol, 95% ethanol, 100% ethanol, 95% ethanol and then
xylene before placing a coverslip on the section. For a negative
control, the primary antibody was omitted.
Apoptotic index. After immunohistochemical staining of
active caspase-3, 10 random lung fields per tissue section were
captured at a 4006 magnification, then the number of active
caspase 3-positive cells was counted by an observer who was
blinded to the coded tissue sections using the AxioVisionH Imaging
System software. The total length of the alveolar perimeters of
each of the captured images was used as the reference of the
caspase-3 positive index.
Quantification of HIF-1a positive cells. The quantification
of HIF-1a positive cells was previously reported [19]. Briefly, after
immunohistochemical stain of HIF-1a, images were acquired and
analyzed using AxioVisionH Imaging System software (Carl Zeiss
Vision GmbH). 10 random lung fields per slide were captured at a
4006 magnification, then the AxioVisionH Imaging System
software was used to measure the total length of the alveolar
perimeters in pixels per mm2, and then the number of HIF-1a
positive cells was counted by an observer who was blinded to the
coded tissue sections.
Figure 3. Apoptotic index of rats from animals with fenretinide
with or without S1P. Immunohistochemical staining for cleaved
caspase-3 was performed and used to calculate the apoptotic index.
After immunohistochemical staining, 10 random lung fields per tissue
section were captured at a 4006magnification, then the number of
active caspase 3-positive cells was counted by an observer who was
blinded to the coded tissue sections using the AxioVisionH Imaging
System software. The total length of the alveolar perimeters of each of
the captured images was used as reference for the caspase-3 positive
index. Data are expressed as mean 6 SEM. C=Control, F = Fenretinide,
S = S1P.
doi:10.1371/journal.pone.0053927.g003
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Mass spectrometric analysis of sphingolipid
metabolites. Fresh frozen (280uC) rat lung tissue was used
for measuring sphingolipid metabolites. After homogenization, an
internal standard cocktail was added (0.5 nmol each C12:0-SM,
C12:0-Cer, C12:0-GlcCer, d17-sphingosine, d17-sphinganine,
d17-sphingosine-1-phosphate, d17-sphinganine-1-phosphate, and
C12:0-Cer-1-phosphate from Avanti Polar Lipids, Alabaster, AL),
lipids extracted, and individual ceramide acyl chain species
quantified after liquid chromatography, the electrospray ioniza-
tion-tandem mass spectrometry (LC-ESI-MS/MS, 4000 QTRAP;
Applied Biosystems, Foster City, CA) as described previously [23].
Data are expressed as pmoles per mg of tissue.
Statistical analysis. All data are expressed as means 6
standard error (S.E.M.). Data were evaluated for significance by
an ANOVA and the Tukey or the Kruskall-Wallis test. Signifi-
cance was determined at P,0.05 (two-tailed test).
Results
Chronic Administration of Fenretinide Induces
Emphysema in Rat Lung
Following four weeks of fenretinide injections, we harvested and
examined the lungs and performed morphometrical analysis.
When compared to control rat lungs, fenretinide treated rats
demonstrated emphysema like airspace enlargement (Fig. 1A
and B). Concurrent S1P administration prevented the air-space
enlargement (Fig. 1C). No morphological changes were observed
after S1P treatment (Fig. 1D). The mean alveolar airspace areas
(MAA) were significantly larger than in control rats (Fig. 1E).
Fenretinide Increases Lung de novo Synthesis of
Ceramide
Sphingolipids were extracted and analyzed by LC-ESI-MS/MS
[23]. In our study, chronic fenretinide treated rat lungs showed
significantly higher levels of dihydroceramide than the control rat
lungs (Figure 2A). We also analyzed long chain species of
dihydroceramide and as indicated in Figure 2B, the main
component of the lung tissue extract dihydroceramide was
C16:0. The results of the statistical analysis for each ceramide
species are also displayed in Figure 2B. In contrast, fenretinide did
not significantly change the ceramide concentration in rat lungs
(data not shown). These results agree with recent studies
demonstrating that fenretinide induces dihydroceramide forma-
tion via both serine palmitoyltransferase and dihydroceramide
synthase [24] while concomitantly inhibiting dihydroceramide
desaturase [25,26], suggesting that dihydroceramide rather than
ceramide mediates the fenretinide-induced effects.
Figure 4. Western blot analysis of cytoplasmic and nuclear proteins (n=4, for each group). Densitometric data and representative protein
bands are shown. HIF-1a, HDAC2 and Nrf2 expression was normalized to a housekeeping protein Lamin B (A, C and D, respectively). VEGF expression
was normalized to b actin (B). Data are expressed as mean 6 SEM. C =Control, F = Fenretinide, S = S1P.
doi:10.1371/journal.pone.0053927.g004
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Chronic Injection of Fenretinide Induces Lung Cell
Apoptosis
Immunohistochemical staining for cleaved caspase-3 was
performed and we calculated the apoptotic index. When
compared to control rats, fenretinide treatment resulted in the
generation of a significantly larger number of cleaved caspase-3
positive cells in the lungs (Figure 3).
Systemic Administration of S1P Reduces
Dihydroceramide Levels and Improves Fenretinide
Induced Airspace Enlargement and Lung Cell Apoptosis
As indicated in Figures 2A and B, intraperitoneal administration
of S1P significantly reduced the dihydroceramide levels in
fenretinide treated rat lungs. S1P administration also reduced
fenretinide-induced lung cell apoptosis (Figure 3) and improved
the emphysema like airspace enlargement of the rat lung
(Figure 1A to E).
Figure 5. Immunohistochemical analysis of HIF-1a. The number of the HIF-1a positive cells is counted in vehicle control, S1P, fenretinide, and
fenretinide with S1P treated rat lungs. Then they were referenced to the total length of the alveolar perimeters (A). Representative images of
immunohistochemical staining of HIF-1a are shown (B). Bars = 50 mm, Original Magnification x100 Data are expressed as mean 6 SEM. C=Control,
F = Fenretinide, S = S1P, TLAP= total length of the alveolar perimeters.
doi:10.1371/journal.pone.0053927.g005
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Fenretinide Disrupts the Signaling of Cell Survival Factors
and Administration of S1P Prevents this Disruption
Having reported that HIF-1a and VEGF operate as lung
structure maintenance factors [9,11,13,19], in particular that HIF-
1a protein expression was suppressed in the lungs from patients
with COPD/emphysema, we next investigated whether the
expression of HIF-1a and VEGF was affected by fenretinide
treatment. Western blot analysis showed significantly reduced
HIF-1a and VEGF protein expression (Figure 4A and B) as a
consequence of chronic fenretinide treatment. HDAC2 and the
transcription factor Nrf2, known to induce a number of
antioxidant genes, were similarly reduced in expression by chronic
fenretinide treatment (Figure 4C and D).
Because HIF-1a protein expression in lung is considered a key
regulator of air space homeostasis, we examined HIF-1a using
immunohistochemical analysis as described previously [19]. A
significantly reduced number of HIF-1a positive cells were seen in
fenretinide treated rat lungs (Figure 5A). S1P treatment alone did
not change the expression of HIF-1a (Figure 4A and 5A, B).
Representative immunohistochemistry is shown in Figure 5B.
Concomitant S1P administration protected the lungs against
these fenretinide-triggered lung tissue protein expression changes.
(Figure 4A to D and 5A, B).
Administration of S1P Induces Phospho-sphingosine
Kinase 1 and Reverses the Ceramide-S1P Imbalance
It has been reported that exogenously administered S1P
activates sphingosine kinase 1 and induces dihydro-S1P formation
[27]. We therefore investigated whether lung tissue sphingosine
kinase 1 was activated following intraperitoneal S1P injection in
fenretinide treated rats. When compared to the lungs from
fenretinide treated rats, injection of fenretinide plus S1P increased
the expression of phosphorylated sphingosine kinase 1 in the lung
tissues (Figure 6A). When compared to the lungs from S1P alone
treated and control rats, exogenous administrations of S1P
protected against the effects of fenretinide treatment (Figure 6A).
Because fenretinide induces dihydroceramide (Figure 2) and
administration of S1P induces dihydro-S1P [25,28], we questioned
whether there was an effect of S1P treatment on the balance
Figure 6. Effect of exogenous S1P on phospho-sphingosine
kinase 1 (pSphk1) and the balance of dihydroceramide and
dihydro-S1P (n =4, each for group). Densitometric data and
representative protein bands are shown. Phospho-Sphk1 was adjusted
to Sphk1 (A). The balance of dihydroceramide/dihydro-S1P was
investigated by mass spectrometric analysis (B). Data are expressed as
mean 6 SEM. C=Control, F = Fenretinide, S = S1P.
doi:10.1371/journal.pone.0053927.g006
Figure 7. The schematic represents the concept of how
fenretinide and exogenously administered sphingosine 1
phosphate (S1P) affect the adult lung structure maintenance.
Administration of fenretinide changes the ceramide/S1P ratio by
increasing the generation of ceramide, which in turn decreases HIF-
1a and VEGF expression in the lung. Reduction of HIF-1alpha and VEGF
-both central to the adult lung structure maintenance program- causes
emphysema (A). Exogenously administered S1P increases the amount
of intracellular S1P via sphingosine kinase 1 (Sphk1) activation (B), thus
protecting against lung cell apoptosis.
doi:10.1371/journal.pone.0053927.g007
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between dihydroceramide and dihydro-S1P. Mass spectrometric
analysis of dihydroceramide and dihydro-S1P revealed that there
was a significant increase of the dihydroceramide/dihydro-S1P
ratio in lung tissues from fenretinide treated rats and that this ratio
was normalized by the administration of S1P (Figure 6B).
Discussion
In this study, we have shown that chronic injection of
fenretinide induced ceramide generation in rat lungs. The
dihydroceramide production disrupted the homeostatic balance
between dihydroceramide and dihydro-S1P, resulting in a
reduction of HIF-1a, and VEGF expression, and lung cell
apoptosis, and alveolar airspace enlargement. Exogenously
administered S1P activated Sphk1 leading to intracellular
production of S1P. Thus increased S1P restored the S1P/
ceramide rheostat, the expression of HIF-1a and VEGF and
prevented lung cell apoptosis. As a result, the airspace enlargement
was prevented.
Although increased ceramide levels in emphysematous lung
tissue have been associated with induction of lung cell apoptosis,
little is known about the role of dihydroceramide, a de novo
pathway ceramide precursor. To begin to examine this pathway
we utilized fenretinide (4-hydroxyphenylretinamide, 4HPR) an
anti-cancer drug which is currently undergoing clinical trials
[20,21]. Fenretinide has been found to affect sphingolipid
metabolism and to increase dihydroceramide levels. Fenretinide
increases dihydroceramide and synergizes with dimethylsphingo-
sine to enhance cancer cell killing [25,26].
Here we expand on the body of work that connects oxidative
stress with ceramide and emphysematous lung destruction [12,14]
by demonstrating that chronic treatment of rats with fenretinide, a
synthetic retinoid, presently in use as an apoptosis-inducing cancer
therapeutic agent [29], causes emphysematous airspace enlarge-
ment. This is to our knowledge the first report of experimentally
induced lung tissue destruction by fenretinide. It has been reported
that ceramides induce lung endothelial cell and epithelial cell
apoptosis [28,30], and we thus examined whether chronic
fenretinide treatment caused lung cell apoptosis. Because fenreti-
nide causes activation of protein kinase C (PKC) [31] and
induction of the transcription factor GADD153 [32], which in
turn have been associated with fenretinide-induced apoptosis, we
examined the expression of cleaved caspase 3 in lungs from
fenretinide treated rats and demonstrated the presence of a large
number of lung structure cells undergoing apoptosis. We therefore
conclude that fenretinide-induced airspace enlargement is due to
lung cell apoptosis.
These results led us to further examine the actions of this
retinoid in the lung in the context of the homeostatic sphingosine-
1-phosphate (S1P)/ceramide balance as previously described by
Takabe et al [15] and by Huwiller and Pfeilschiffer [33]. S1P acts
on intracellular targets, but S1P is also released from cells and acts
on cell surface S1P receptors in an autocrine or paracrine fashion
[17]. Whereas S1P is proangiogenic and suppresses apoptosis,
ceramide induces apoptosis. Together Sphingosine, S1P and
ceramide represent a rheostat which determines cell fate [34].
Whereas Petrache et al [12] showed that one consequence of
VEGF receptor blockade was ceramide production in the lung
tissue, we stimulated ceramide production by systemically
administering fenretinide. Our finding that fenretinide caused an
increase in the tissue levels of dihydroceramide indicates activation
of the endoplasmic reticulum-localized de novo biosynthetic
pathway of sphingolipids [35]; the most abundant dihydrocer-
amide species produced in the lung by fenretinide was C16:0
dihydroceramide (Figure 2B).
We also showed that exogenously administered S1P did protect
against fenretinide-induced lung cell apoptosis (Figure 3) and
emphysema (Figure 1). This is surprising because intraperitoneal
injection of S1P- which has a short biological half-life -was
effective in neutralizing the ceramide actions in the lung. The
protective effect of injected S1P was associated with the
preservation of the transcription factorHIF-1a expression
(Figure 5) and increased Nrf2 expression. In addition, we also
found that the reduction in the expression of HDAC2 was
prevented by S1P. The HDAC expression reduction was
accompanied by a decrease in the expression of the HIF-1a and
VEGF (Figure 4). As we have previously reported [11,36,37],
inflammation was assessed histologically in this model, i.e.,
multiple tissue sections were examined, and inflammatory cell
infiltrates and accumulations of alveolar macrophages or neutro-
phils were not found in the lung parenchyma or immediate
peribronchial or perivascular areas. At least in rats emphysema
associated with decreased expression of HDAC2, HIF-1a and
VEGF is not due to inflammation. However, our data recapitulate
findings obtained after the examination of lung tissue extracts from
patients with COPD: reduced VEGF [9] and HDAC2 protein
[19] expression. In the lung tissue samples from COPD patients
diminished expression of the gene controlling the expression of a
number of antioxidant enzymes, Nrf2, has previously been
reported [38,39]. However, in the fenretinide treated rat lungs,
we observed increased Nrf2 protein expression perhaps reflecting
an attempt of the tissue to counter ceramide-related oxidant stress.
Thus, with the exception of the Nrf2 expression, the pattern of
reduced protein expression found in COPD lungs was also
detected in the lungs from fenretinide treated emphysematous
animals (Figure 4).
There are a number of known interactions between HIF-1a and
sphingolipids [18,40,41] and also between S1P and HDAC [42].
For example HIF-1a is a sphingosine kinase 1 regulated gene
[42,43] and HDACs appear to be intracellular targets of S1P
[43,44]. That fenretinide can alter HDAC expression has not been
previously reported (Figure 4C).
It is known that exogenous S1P activates sphingosine kinase 1
and increases intracellular S1P [27], and here we show that i.p.
injection of S1P increased the amount of phosphorylated
sphingosine kinase 1 in the lung tissue from chronically fenretinide
treated rats (Figure 6A). In addition, S1P normalized the
dihydroceramide/dihydro-S1P ratio in the lung tissue (Figure 6B).
Taken together, our experimental data support the concept that
fenretinide, via dihydroceramide, causes airspace enlargement
which can be prevented by exogenous S1P (Figure 1A–E), which
in turn maintains HIF-1a protein expression and the expression of
the HIF-1a target gene VEGF (Figure 4 A and B). We speculate
that fenretinide induces endothelial cell apoptosis (Figure 3, 7A)
and that lung endothelial cell-derived S1P ‘‘buffers’’ the action of
ceramides generated after fenretinide treatment (Figure 7B). It has
previously been shown that fenretinide causes endothelial cell
apoptosis and it has been suggested that ceramide signals upstream
from caspases [44,45]. Fenretinide has been shown to inhibit tube
formation in angiogenesis assays [46] and dihydroceramide likely
is responsible for the antiangiogenic action of fenretinide. In our
experiments, fenretinide treatment caused a reduction in the lung
tissue HIF-1a protein which was prevented by concomitant S1P
treatment (Figure 4A, 5A, B), while S1P treatment increased Nrf2
protein expression (Figure 4D). We propose that the administra-
tion of exogenous S1P has induced intracellular S1P via
sphingosine kinase 1 activation (Figure 6A). Whether the
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protective/preventative action of administered S1P during fenre-
tinide challenge of the animals was due to the upregulation of
HDAC2 (Figure 4C) or VEGF or Nrf2- or due to a combination of
these effects, or other S1P controlled actions, for example, effects
of S1P on lipoxygenases [47], remains unclear.
We have previously suggested that disruptions of the adult lung
maintenance program causes emphysema [8,48]. First, we
described that the disruption of VEGF signaling causes lung cell
apoptosis and alveolar air space enlargement [11]. In follow-up
studies we showed that downregulation of HIF-1a by copper
depletion [36] or HDAC inhibition [37] causes downregulation of
VEGF expression, lung cell apoptosis, and alveolar enlargement.
Apparently ‘‘too much or too little of VEGF is catastrophic to the
lung’’ [49]. The homeostatic concept of the ‘‘adult lung cell
maintenance program’’ can explain how the adult lung maintains
its structural integrity. This concept is based on the postulate that
there are factors which are of fundamental importance for the
proper maintenance of the organ structure such as HIF-1a and
VEGF [48]. We now propose to add the S1P/ceramide balance or
‘‘rheostat’’ to the repertoire of lung structure maintenance factors.
An offset of the S1P/ceramide rheostat affects the expression of
HDAC, HIF-1a and VEGF resulting in lung cell apoptosis
(Figure 7A). Exogenous administration of S1P activates Sphk1 to
generate intracellular S1P and resets the rheostat, thus preventing
emphysematous development (Figure 7B).
In conclusion, our experiments support the concept that
emphysematous lung tissue destruction can occur independent of
inflammation via an imbalance of the S1P/ceramide homeostasis.
This ‘‘sphingolipid rheostat’’ appears to influence HIF-1a-
dependent VEGF transcription, and HDAC2 and Nrf2 expres-
sion. Each of these factors are components of the adult lung
structure maintenance program [48].
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